TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Decrease in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a significant decline in short interest in the month of May. As of May 31st, there was short interest totalling 32,700 shares, a decline of 70.0% from the May 15th total of 109,000 shares. Currently, 0.2% of the company's shares are short sold. Based on an average daily trading volume, of 48,800 shares, the days-to-cover ratio is currently 0.7 days.

Insider Activity at TriSalus Life Sciences

In related news, insider Richard Marshak sold 6,597 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the transaction, the insider now owns 69,101 shares in the company, valued at $357,943.18. The trade was a 8.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 16,125 shares of company stock worth $83,528 over the last 90 days. 27.50% of the stock is owned by company insiders.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. purchased a new position in TriSalus Life Sciences during the first quarter valued at $55,000. Renaissance Technologies LLC purchased a new position in shares of TriSalus Life Sciences in the 4th quarter worth $67,000. Connective Capital Management LLC bought a new stake in shares of TriSalus Life Sciences in the 4th quarter worth about $140,000. Northern Trust Corp lifted its holdings in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after acquiring an additional 5,936 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of TriSalus Life Sciences in the 1st quarter worth about $187,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Stock Down 5.6%

TLSI traded down $0.31 during trading on Friday, hitting $5.19. The company's stock had a trading volume of 34,602 shares, compared to its average volume of 42,291. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $6.18. The firm has a market cap of $196.38 million, a PE ratio of -2.08 and a beta of 0.47. The business's 50 day simple moving average is $5.41 and its 200-day simple moving average is $5.16.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the previous year, the firm earned ($0.60) EPS. Equities research analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TLSI has been the topic of a number of recent research reports. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital assumed coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They set a "buy" rating and a $10.00 price target on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $10.75.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.